# Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.

> **NCT02417831** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 34 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** tamsulosin capsules
- **DRUG:** tamsulosin HCl

## Key facts

- **NCT ID:** NCT02417831
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-30
- **Primary completion:** 2015-05-31
- **Final completion:** 2015-05-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02417831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02417831, "Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02417831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*